MDG1 MediGene AG

Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

MARTINSRIED, Germany and MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Wednesday, 6 January 2021 from 8:00 am EST.

The panel, entitled “Challenges and Opportunities in Cell Therapy”, will explore the potential of next generations of cell therapy to respond to current hurdles and challenges and how these will be positioned in the current treatment paradigm. Investors can pre-register for the panel discussion .

About Medigene

Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene

Dr. Gary Waanders, Dr. Anna Niedl

Phone: 3 01

e-mail:

LifeSci Advisors

Mary-Ann Chang

Phone: 3

e-mail:

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (). We will then delete your address from our distribution list.



EN
05/01/2021

Underlying

MDG1MediGene AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediGene AG

 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene Files Patent for Unique NK-Specific TCR Construct with Europe...

Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the submission of a patent for a novel natural killer (NK) cell-specific TCR construct to the European Patent Office. With that, Medigene is advancing its TCR-guided strategy by expanding the application of its proprietary 3S (sensitive, specific, and safe) TCRs into NK cells. This patent application marks a majo...

March 13, 2025 1 EN
 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partne...

Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers  Planegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors. The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S ...

February 27, 2025 1 EN
 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Te...

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S. Planegg/Martinsried, February 19, 2025. (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today that the Company has been issued a patent by the U.S. Patent Office protecting its JOVI technology, a method allowing the enrichment of T cells using a specific anti-Cβ antibody. The U.S. patent for the JOVI technology was granted at the end of last year with the offi...

February 19, 2025 1 EN
 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene AG announces closing of its first SEPA tranche

Medigene AG announces closing of its first SEPA tranche Planegg/Martinsried, February 3, 2025. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced the closing of its first tranche of the Standby Equity Purchase Agreement (“SEPA”) with a fund managed by Yorkville Advisors Global, LP (“Yorkville”) announced on January 24, 2024. The subscription price was set at EUR 1.70 and is equal to 95% of the average of the volume-weighted average pric...

February 3, 2025 1 EN
 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell ...

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers Planegg/Martinsried, December 9, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the selection of Kirsten rat sarcoma viral oncogene homologue (KRAS) G12V, in the context of HLA*A11, as the initial target for the co-development of T cell receptor-guided T cell engagers (TCR-TCEs) with WuXi Biologics. The selection of this first target is a key...

December 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch